Sanofi India reported a mixed set of numbers for the March quarter, with a notable improvement in operational performance offsetting a decline in net profit. For Q4 FY25, net profit fell 12.5% year-on-year to ₹119.5 crore, down from ₹136.6 crore in the same quarter last year. However, revenue rose nearly 5% YoY to ₹535.9 crore, driven by steady growth in its core therapy areas.
A key highlight of the quarter was the strong expansion in profitability metrics. EBITDA rose sharply by 25% YoY to ₹171.9 crore, compared to ₹137.5 crore in Q4 FY24. Margins also expanded significantly to 32.1%, up from 26.9% a year ago. The company attributed the improvement to strong cost controls and enhanced operating efficiencies across the business.
The launch of Soliqua®, Sanofi’s new diabetes drug in the premix segment, played a pivotal role in driving growth and further strengthening the company’s diabetes portfolio. On a comparable basis of continuing business, Sanofi India reported a 4% growth in net sales for the quarter.
Commenting on the performance, Rachid Ayari, Whole Time Director and CFO, said, “The Company has delivered a strong first quarter performance reflecting Sanofi’s successful strategy for India. We will continue to focus on driving further improvement in operating efficiencies while expanding the availability of our best-in-class innovative products in India.”
Shares of Sanofi India were trading over 2% higher following the results, indicating investor confidence in the company’s operational outlook despite the dip in quarterly net profit.
